Skip to main content

Table 1 Characteristics of K. pneumoniae infections according susceptibility to carbapenems

From: Risk factors and survival of patients infected with carbapenem-resistant Klebsiella pneumoniae in a KPC endemic setting: a case-control and cohort study

Characteristics Carbapenem-susceptible K. pneumoniae n = 289 Carbapenem-resistant K. pneumoniae n = 49 Total K. pneumoniae infections n = 338
n % n % n %
Site of infection
 Urinary tract infection (UTI) 82 28.37 13 26.53 95 28.11
 Intra-abdominal infection 67 23.18 6 12.24 73 21.60
 Surgical site infection 24 8.30 8 16.33 32 9.47
 Bacteriemia 25 8.65 5 10.20 30 8.88
 Catheter associated UTI 19 6.57 6 12.24 25 7.40
 Pneumonia 19 6.57 3 6.12 22 6.51
 Skin and soft tissue infections 18 6.23 2 4.08 20 5.92
Empirical treatment 262 90.66 45 91.84 307 90.83
 Piperacillin/Tazobactam 169 58.48 21 42.86 190 56.21
 Meropenem 59 20.42 21 42.86 80 23.67
Targeted treatment 270 93.43 39 79.59 309 91.42
 Meropenem 125 43.25 30 61.22 155 45.86
 Ciprofloxacin 49 16.96 4 8.16 53 15.68
 Tigecycline 2 0.69 18 36.73 20 5.92
 Colistin 0 0.00 10 20.41 10 2.96
Combined therapy 45 15.57 33 67.35 78 23.08
Surgical treatment 89 30.80 11 22.45 100 29.59
Hospital length stay (median, IQR) 18 (10–33) 26 (13–42) 19 (10–34)
30-day mortality (all-causes) 46 15.92 16 32.65 62 18.34